Cerebrocortical beta activity in overweight humans responds to insulin detemir.

Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany.
PLoS ONE (Impact Factor: 3.53). 02/2007; 2(11):e1196. DOI: 10.1371/journal.pone.0001196
Source: PubMed

ABSTRACT Insulin stimulates cerebrocortical beta and theta activity in lean humans. This effect is reduced in obese individuals indicating cerebrocortical insulin resistance. In the present study we tested whether insulin detemir is a suitable tool to restore the cerebral insulin response in overweight humans. This approach is based on studies in mice where we could recently demonstrate increased brain tissue concentrations of insulin and increased insulin signaling in the hypothalamus and cerebral cortex following peripheral injection of insulin detemir.
We studied activity of the cerebral cortex using magnetoencephalography in 12 lean and 34 overweight non-diabetic humans during a 2-step hyperinsulinemic euglycemic clamp (each step 90 min) with human insulin (HI) and saline infusion (S). In 10 overweight subjects we additionally performed the euglycemic clamp with insulin detemir (D). While human insulin administration did not change cerebrocortical activity relative to saline (p = 0.90) in overweight subjects, beta activity increased during D administration (basal 59+/-3 fT, 1(st) step 62+/-3 fT, 2(nd) step 66+/-5, p = 0.001, D vs. HI). As under this condition glucose infusion rates were lower with D than with HI (p = 0.003), it can be excluded that the cerebral effect is the consequence of a systemic effect. The total effect of insulin detemir on beta activity was not different from the human insulin effect in lean subjects (p = 0.78).
Despite cerebrocortical resistance to human insulin, insulin detemir increased beta activity in overweight human subjects similarly as human insulin in lean subjects. These data suggest that the decreased cerebral beta activity response in overweight subjects can be restored by insulin detemir.


Available from: Katarína Štingl, May 28, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: This sub-analysis of SOLVE study was to evaluate the safety and efficacy of once daily insulin detemir as add-on to oral anti-diabetic drugs (OADs) in different body mass index (BMI) subgroups of Chinese type 2 diabetes patients in real-life setting.
    Journal of Diabetes 06/2014; 7(2). DOI:10.1111/1753-0407.12179 · 2.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is a disease in which a person has a high blood glucose level as a result of either because the body does not produce enough insulin (Type 1), or because the body cells do not properly respond or resistant to the insulin that is produced (Type 2). Insuin therapy is widely used in patients with these two types of diabetes. Modification of the human insulin molecule results in a slower distribution to peripheral target tissues, a longer duration of action with stable concentrations and thus a lower rate of hypoglycemia. Insulin analogs are synthesized to minimize unpredictable side effects of NPH (neutral protamine Hagedorn) insulin. Insulin detemir is an insulin analog that provides effective therapeutic options for patients with type 1 and type 2 diabetes. Several trials showed that insulin detemir did not display any significant differences in glycated hemoglobin (HbA 1c) levels when compared to NPH and insulin glargine. It is comparable with insulin glargine in significantly reducing rates of all types of hypoglycemia. Clinical studies have demonstrated that detemir enabled significantly lower within-subject variability and no or less weight gain than NPH insulin and glargine. Recent pharmacodynamic studies have pointed out that detemir could be used once daily in many patients with diabetes. This review will focus on the toxicological profile of insulin detemir: pharmaco/toxico-kinetics and dynamics, safety/efficacy, adverse reactions, drug interactions, and its mutagenecity/carcinogenicity.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies in rodents have demonstrated that insulin in the central nervous system induces satiety. In humans, these effects are less well established. Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral Protamine Hagedorn (NPH) insulin. Due to its structural modifications, which render the molecule more lipophilic, it was proposed that insulin detemir enters the brain more readily than other insulins. The aim of this study was to investigate whether insulin detemir treatment differentially modifies brain activation in response to food stimuli as compared to NPH insulin. In addition, cerebral spinal fluid (CSF) insulin levels were measured after both treatments. Brain responses to viewing food and non-food pictures were measured using functional Magnetic Resonance Imaging in 32 type 1 diabetic patients, after each of two 12-week treatment periods with insulin detemir and NPH insulin, respectively, both combined with prandial insulin aspart. CSF insulin levels were determined in a subgroup. Insulin detemir decreased body weight by 0.8 kg and NPH insulin increased weight by 0.5 kg (p = 0.02 for difference), while both treatments resulted in similar glycemic control. After treatment with insulin detemir, as compared to NPH insulin, brain activation was significantly lower in bilateral insula in response to visual food stimuli, compared to NPH (p = 0.02 for right and p = 0.05 for left insula). Also, CSF insulin levels were higher compared to those with NPH insulin treatment (p = 0.003). Our findings support the hypothesis that in type 1 diabetic patients, the weight sparing effect of insulin detemir may be mediated by its enhanced action on the central nervous system, resulting in blunted activation in bilateral insula, an appetite-regulating brain region, in response to food stimuli. NCT00626080.
    PLoS ONE 04/2014; 9(4):e94483. DOI:10.1371/journal.pone.0094483 · 3.53 Impact Factor